CYTH: Cyclo Therapeutics Inc - Class A Company Profile & Statistics

About

Cyclo Therapeutics Inc. is a clinical-stage biotechnology company. It develops cyclodextrin-based products for the treatment of disease. The company's Trappsol(R) Cyclo(TM), an orphan drug designated product primarily in the United States and Europe, is in ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. Cyclo Therapeutics Inc., formerly known as CTD Holdings Inc., is based in ALACHUA, Fla.

Info & Links

CEO

N. Scott Fine

Headquarters

6714 NW 16TH STREET, SUITE B
GAINESVILLE, FL 32653, UNITED STATES

Auditor

WithumSmith Brown PC

Share holders

185

Employees

Cyclo Therapeutics Inc - Class A Statistics

Valuation Measures

Market Capitalization²

19.56M

Enterprise Value

30.81M

Enterprise Value/EBITDA(ttm)

-1.25

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

19.15

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

92.78%

Operating Margin(ttm)

-2678.76%

Profit Margin(ttm)

-3148.59%

Return on Equity(ttm)

-2741.89%

Return on Invested Capital(ttm)

-648.26%

Return on Assets(ttm)

-307.16%

Income Statement

Revenue(ttm)

870.80K

Revenue Per Share(ttm)

0.03

Gross Profit(ttm)

813.20K

EBITDA(ttm)³

-24.68M

Net Income Available to Common(ttm)

-24.80M

Diluted EPS(ttm)

-0.90

Share Statistics

Beta (5Y Monthly)

-0.46

52-Week Change

-59.51%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

28.77M

Dividend Yield

0.00%

Float⁴

20.20M

% Held by Insiders

29.78%

% Held by Institutions

68.55%

Balance Sheet

Total Cash(mrq)

928.00K

Total Cash Per Share(mrq)

0.03

Total Debt(mrq)

12.18M

Total Debt/Equity(mrq)

-90.39%

Current Ratio(mrq)

0.17%

Quick Ratio(mrq)

0.16%

Book Value Per Share(mrq)

-0.47

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.63

Free Cash Flow(ytd)

-18.22M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CYTH

Cyclo Therapeutics Inc - Class A

Cyclo Therapeutics Inc - Class A Profile